methyl 2-[(3R)-5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1-oxo-2,3-dihydrocyclopenta[b]indol-3-yl]acetate | 571170-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: methyl 2-[(3R)-5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1-oxo-2,3-dihydrocyclopenta[b]indol-3-yl]acetate
• CAS: 571170-90-6
• 化学式: C₂₁H₁₆BrClFNO₃
• 分子量: 464.718
• InChiKey: PSUIHYHJPDLTHJ-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  48.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-[(3R)-5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1-oxo-2,3-dihydrocyclopenta[b]indol-3-yl]acetate 在 N-甲基吡咯烷酮 、 sodium hydroxide 、 copper(l) iodide 作用下， 以 四氢呋喃 为溶剂， 生成 LI7K2MH2IJ
  参考文献：
  名称：

  In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites

  摘要：

  Metabolites of the potent DP antagonist, MK-0524, were generated using in vitro systems including hepatic microsomes and hepatocytes. Four metabolites (two hydroxylated diastereomers, a ketone and an acyl glucuronide) were characterized by LC-MS/MS and H-1 NMR. Larger quantities of these metabolites were prepared by either organic synthesis or biosynthetically to be used as standards in other studies. The propensity for covalent binding was assessed and was found to be acceptable (< 50 pmol-equiv/mg protein). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.055
• 作为产物：
  描述：

  [(R)-5-Bromo-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 methyl 2-[(3R)-5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1-oxo-2,3-dihydrocyclopenta[b]indol-3-yl]acetate
  参考文献：
  名称：

  In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites

  摘要：

  Metabolites of the potent DP antagonist, MK-0524, were generated using in vitro systems including hepatic microsomes and hepatocytes. Four metabolites (two hydroxylated diastereomers, a ketone and an acyl glucuronide) were characterized by LC-MS/MS and H-1 NMR. Larger quantities of these metabolites were prepared by either organic synthesis or biosynthetically to be used as standards in other studies. The propensity for covalent binding was assessed and was found to be acceptable (< 50 pmol-equiv/mg protein). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.055

文献信息

• FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
  申请人：Berthelette Carl

  公开号：US20120115921A1

  公开（公告）日：2012-05-10

  Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

  含氟取代的环烷基吲哚衍生物是前列腺素拮抗剂，因此对于治疗前列腺素介导的疾病非常有用。
• Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
  申请人：Berthelette Carl

  公开号：US20080033028A1

  公开（公告）日：2008-02-07

  Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

  氟代环烷基吲哚衍生物是前列腺素拮抗剂，因此对于治疗前列腺素介导的疾病非常有用。
• US7317036B2
  申请人：——

  公开号：US7317036B2

  公开（公告）日：2008-01-08
• US7618994B2
  申请人：——

  公开号：US7618994B2

  公开（公告）日：2009-11-17